Loading clinical trials...
Loading clinical trials...
A Unique Quadruple Regimen for of Helicobacter Pylori
The triple treatment including Proton pump inhibitor (PPI) -clarithromycin and amoxicillin or metronidazole was proposed 30 years ago at the first Maastricht conference to treat helicobacter pylori (H. pylori) infection and since that time, it has become the universal and standard treatment for helicobacter pylori. However, the efficacy of this triple regimen has been seriously challenged, and they are gradually becoming ineffective
Growing rates of treatment failure are observed worldwide and the eradication rate of triple therapy has declined over the past few decades. Helicobacter pylori infection has become increasingly resistant to traditional first line treatment regimens because of emerging antibiotic resistance coupled with poor patient compliance with completing the treatment course that decrease H. pylori eradication rates .So there is a considerable interest in evaluating new antibiotic combinations and regimens .
Age
21 - No limit years
Sex
ALL
Healthy Volunteers
No
Sherief Abd-Elsalam
Tanta, Egypt
Start Date
April 1, 2018
Primary Completion Date
April 1, 2023
Completion Date
April 1, 2023
Last Updated
April 10, 2018
600
ESTIMATED participants
Quadruple therapy
DRUG
Classic treatment
DRUG
Lead Sponsor
Sherief Abd-Elsalam
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions